Overview

Data as of August 02, 2021 07:02 pm EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Summary Toggle Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer

August 02, 2021

CONSHOHOCKEN, Pa. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals , a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Dr.
Summary Toggle Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

July 13, 2021

CONSHOHOCKEN, Pa. , July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension study of MAESTRO-NAFLD-1, named MAESTRO-NAFLD-1-Open Label Extension (OLE) (NCT04951219).
Summary Toggle Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

June 30, 2021

CONSHOHOCKEN, Pa. , June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL ) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO- NASH . Serial liver biopsy and safety data from patients enrolled in MAESTRO- NASH coupled with

Filing date	Form	Description	Filing Group	View
July 05, 2017	D		Other	0001288452-17-000002.rtf 0001288452-17-000002.pdf
December 12, 2019	424B7	424B7	Registration Statements	0001193125-19-312878.rtf 0001193125-19-312878.xls 0001193125-19-312878.pdf
April 17, 2013	PRE 14A	A preliminary proxy statement providing notification matters to be brought to a vote	Proxy Filings	0001047469-13-004491.rtf 0001047469-13-004491.xls 0001047469-13-004491.pdf